Clinical trial · Interventional
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
NCT01024062CI-TRIAL-00004724completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent non-small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Paclitaxel
- interventionNames
- Drug: Paclitaxel
Primary outcomes (2)
- measure
- Response rate [defined as total number of patients with complete and partial response divided by number of response-evaluable patients] based on "Response Evaluation Criteria in Solid Tumors (RECIST)" in patients with no prior chemotherapy
- timeFrame
- Each 49 day course of treatment until withdrawal or unacceptable toxicity
- measure
- Safety: incidence and severity of adverse events, laboratory test abnormalities
- timeFrame
- Each 49 day course of treatment until withdrawal or unacceptable toxicity
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with no prior chemotherapy who meet either of the listed below: * Patient with stage IIIB or IV disease * Patients with recurrent disease following potentially curative surgical resection * Patients with previous chemotherapy up to one regimen Exclusion Criteria: * Patients with serious, uncontrolled medical illness * Patients with previous therapy with taxanes
References
Publications (0)
Data not yet available
No reference posted for this study.